About
Laura Deming is CEO and co-founder of Until, a company focused on aging and age-related disease. She began working in biogerontology at age 12 and attended MIT starting at age 14. Deming was a Thiel Fellow at 17 and has worked as a venture capital partner at The Longevity Fund, investing in gene editing, small molecule therapeutics, and disease treatment approaches.
Experience
- UntilCEO, co-foundercurrent2024 — presentSouth San Francisco, California, United States
- age1Partnercurrent2023 — presentSan Francisco Bay Area
- The Longevity FundPartnercurrent2011 — presentSan Francisco
- Alexo Therapeutics.2015 — 2016
- The Thiel FoundationThiel Fellow2011 — 2013San Francisco
- GenentechResearcher - Firestein Lab2011South San Francisco
- Weiss Lab, MITResearcher2010 — 2011
- iGEM (International Genetically Engineered Machine Competition), MITResearcher2010
- Guarente Laboratory (MIT)Researcher2009 — 2010
- Kenyon Laboratory (UCSF)Researcher2006 — 2009
Education
- Massachussetts Institute of Technology (MIT)On Leave from a Bachelor of Science, Physics and Biology2009 — 2011
- University of California, San Francisco2007 — 2009
Skills & more
Biochemistry41Genetics27Regenerative Medicine8Cell Based Assays3Protein Chemistry14DNA14Cancer15Cell17Lifesciences28
From Laura's professional profile.
Colleagues at age1
Alex Colville
Co-Founder, General Partner at age1
Carol Magalhaes
NewCo Chief of Staff at age1
Doug Henze
Venture Fellow at age1
Lauren Naworski
Venture Fellow at age1
Lily Clayton
Head of Operations at age1
Lynetta Wang
Venture Intern at age1
Maggie Li
Special Projects Lead at age1
Satvik Dasariraju
Principal at age1